Women's HRT: What It Is, How It Works, and What the Evidence Actually Says

What Is Women's HRT and Who Qualifies for It

Women's HRT replaces the hormones, primarily estradiol and progesterone, that the ovaries produce in decreasing amounts from perimenopause onward. Any woman with bothersome menopause symptoms, premature ovarian insufficiency (POI) before age 40, or surgical menopause may be a candidate. The Menopause Society's 2023 position statement states directly: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." [1]

Perimenopause begins, on average, four years before the final menstrual period and involves erratic estrogen fluctuation rather than simple decline. [2] Women in this stage often experience the worst vasomotor symptoms precisely because estrogen levels swing unpredictably. HRT stabilizes that fluctuation. Surgical menopause, which removes the ovaries entirely, causes an abrupt estrogen drop that tends to produce more severe symptoms than natural menopause, and HRT started immediately after surgery generally produces the clearest benefit. [3]

POI affects approximately 1% of women under 40. [4] For these women, HRT serves a protective function beyond symptom relief, reducing long-term cardiovascular and bone risks associated with decades of estrogen deficiency. The European Society of Human Reproduction and Embryology recommends HRT for POI patients until at least age 51 (average natural menopause age) unless contraindicated. [5]

Contraindications include unexplained vaginal bleeding, active or recent estrogen-sensitive breast or endometrial cancer, active venous thromboembolism, and uncontrolled hypertension. Women with a personal history of cardiovascular disease should have an individualized risk assessment before starting. [6]

Types of HRT: Estrogen-Only vs. Combined Therapy

The choice between estrogen-only and combined HRT depends on whether the uterus is intact. Estrogen alone, given to women who have had a hysterectomy, avoids the progestogen-related risks that concern some patients. Women who still have a uterus must take a progestogen alongside estrogen to prevent endometrial hyperplasia and cancer. [7]

Progestogen options matter. Synthetic progestins such as medroxyprogesterone acetate (MPA), used in the original WHI trial, carry a different risk profile than micronized progesterone (Prometrium, 200 mg nightly). The E3N cohort study (N=80,377) found that combined estrogen plus micronized progesterone did not significantly raise breast cancer risk over 8.1 years of follow-up, whereas estrogen plus synthetic progestins did. [8] That distinction shapes many current prescribing decisions.

Estrogen delivery routes differ meaningfully in first-pass metabolism. Oral estradiol passes through the liver and raises sex hormone-binding globulin and clotting factors more than transdermal preparations do. A nested case-control study in the BMJ (N=15,710 VTE cases) found that transdermal estradiol was not associated with increased VTE risk while oral estradiol was, with an odds ratio of 2.1 (95% CI 1.3-3.4). [9] For women with a personal or family history of clot disorders, transdermal delivery is the preferred route per NICE guideline NG23. [10]

Vaginal estrogen is a low-dose, locally acting option for genitourinary syndrome of menopause (GSM) only. It produces negligible systemic absorption at standard doses and is not considered systemic HRT. The FDA has approved several vaginal preparations including estradiol (Vagifem, Imvexxy) and conjugated equine estrogen (Premarin cream). [11]

What the WHI Actually Found (and What It Did Not)

The Women's Health Initiative, published in JAMA in 2002, enrolled 16,608 postmenopausal women aged 50-79 and randomized them to conjugated equine estrogen (0.625 mg) plus MPA (2.5 mg) or placebo. [12] The trial was stopped at 5.2 years after interim analyses showed a hazard ratio of 1.26 for invasive breast cancer and 1.29 for coronary heart disease. Media coverage at the time led to a 50% drop in HRT prescriptions within two years.

Later reanalysis changed the picture substantially. The 2013 WHI reanalysis by Manson et al., published in JAMA, stratified results by age and years since menopause. [13] Women who started HRT at ages 50-59 (within 10 years of menopause onset) showed a significantly lower all-cause mortality: hazard ratio 0.69 (95% CI 0.51-0.94) in the estrogen-only arm. The breast cancer signal was largely confined to women who had used progestins before the trial and to older initiators. This reanalysis gave rise to the "timing hypothesis," also called the "window of opportunity" concept.

The WHI Memory Study (WHIMS), an ancillary trial, found increased dementia risk with combined HRT in women aged 65 and older. [14] However, this population was well past the timing window. No randomized controlled trial has shown increased dementia risk in women who initiate HRT before age 60. The KEEPS trial (N=727, mean age 52.6) found no adverse cognitive effects over 4 years of either oral conjugated equine estrogen or transdermal estradiol. [15]

Bone outcomes remain consistently favorable. The WHI showed a 34% reduction in hip fracture risk (HR 0.66 to 95% CI 0.45-0.98) and a 24% reduction in total fractures (HR 0.76 to 95% CI 0.69-0.83) in the combined HRT arm. [12]

Cardiovascular Effects and the Timing Hypothesis

The timing hypothesis holds that estrogen protects the cardiovascular system in women with early-stage atherosclerosis but may destabilize existing plaques in women with advanced disease. This explains the discordance between observational studies showing cardiac benefit and the WHI finding of early harm in its older cohort.

The ELITE trial (N=643) randomized recently menopausal women (less than 6 years since menopause) versus late postmenopausal women (more than 10 years) to oral estradiol or placebo. [16] In recently menopausal women, oral estradiol slowed progression of carotid intima-media thickness (CIMT) compared to placebo. In the late group, no benefit appeared. This mechanistic finding directly supports the timing hypothesis and was published in the New England Journal of Medicine.

The American Heart Association published a scientific statement in 2020 noting that "observational data consistently show that women who initiate MHT soon after menopause have reduced coronary heart disease events and all-cause mortality," while cautioning that HRT is not indicated as a primary prevention strategy for cardiovascular disease. [17] The distinction between these two statements, that HRT does not harm cardiovascular health in early menopause but also is not a CV medication, guides current clinical practice.

Breast Cancer Risk: Putting the Numbers in Context

The absolute risk increase from combined estrogen-progestogen HRT is small but real. WHI data show approximately 8 additional breast cancer cases per 10,000 woman-years of combined HRT use. [12] For context, drinking one alcoholic drink per day adds roughly 7 cases per 10,000 woman-years, and a BMI over 35 adds considerably more. [18]

Estrogen-only HRT in women without a uterus did not increase breast cancer risk in the WHI. After 7.1 years of follow-up, the estrogen-only arm actually showed a non-significant trend toward fewer breast cancers (HR 0.77 to 95% CI 0.59-1.01). [19]

Duration matters. The Collaborative Group on Hormonal Factors in Breast Cancer (2019 meta-analysis, N=108,647 breast cancer cases) found that risk increases with duration of use and that past use of combined HRT for less than one year did not significantly raise risk. [20] Women considering short-term HRT (under 5 years) for symptom management carry a substantially smaller absolute risk than those using it for a decade or more.

Progestogen choice appears to modify risk independently. The re-analysis of the E3N cohort confirmed lower breast cancer incidence with micronized progesterone versus synthetic progestins, a finding that has shaped European and UK prescribing patterns toward body-identical progesterone. [8]

Genitourinary Syndrome of Menopause (GSM)

GSM affects approximately 50-60% of postmenopausal women and includes vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. [21] Unlike vasomotor symptoms, GSM does not resolve spontaneously over time and often worsens without treatment.

Local vaginal estrogen is first-line therapy for GSM without systemic HRT. The FDA-approved estradiol vaginal insert (Vagifem 10 mcg) used twice weekly after an initial daily loading phase has shown efficacy in reducing the vaginal maturation index and improving pH in multiple randomized trials. [11] Ospemifene (Osphena), a selective estrogen receptor modulator taken orally at 60 mg daily, is an alternative for women who prefer non-hormonal vaginal treatment.

For women already on systemic HRT who still experience GSM, adding low-dose vaginal estrogen is safe. Systemic HRT alone may not deliver sufficient local estrogen to urogenital tissues in all women. A 2018 Cochrane review of 30 trials found that local estrogen treatments significantly improved vaginal dryness, dyspareunia, and urinary symptoms versus placebo, with minimal systemic absorption. [22]

Bioidentical vs. Conventional HRT

The term "bioidentical" describes hormones with a molecular structure identical to those produced by the human body. FDA-approved bioidentical preparations include 17-beta estradiol (available as patches such as Vivelle-Dot and Climara, gels such as EstroGel, and oral tablets such as Estrace) and micronized progesterone (Prometrium 100 mg and 200 mg capsules). These are manufactured under rigorous quality standards and have published efficacy and safety data. [23]

Compounded bioidentical HRT (cBHRT), prepared by compounding pharmacies, is different. The FDA does not approve or test these products, and their potency, purity, and absorption can vary batch to batch. The Endocrine Society position statement advises against routine use of compounded HRT when FDA-approved alternatives exist, citing lack of standardization and absence of large-scale safety data. [24] Women seeking body-identical hormones can obtain them through FDA-approved 17-beta estradiol and Prometrium without turning to compounding.

Saliva and urine hormone testing, marketed to guide compounded HRT dosing, have not been validated for this purpose. Hormone levels in saliva do not reliably reflect tissue levels and vary with time of day and dietary factors. [25]

The HealthRX clinical team uses a structured initiation checklist for women requesting HRT. The checklist grades candidates into four tiers based on time since last menstrual period, uterine status, personal cardiovascular and thrombotic history, and personal or first-degree family history of estrogen-sensitive cancers. Tier 1 candidates (aged 45-59, within 10 years of menopause, no significant comorbidities) proceed to transdermal estradiol with micronized progesterone as the default regimen. Tiers 2-4 involve additional specialist input before prescribing. This framework standardizes risk stratification across all HealthRX providers.

Dosing, Regimens, and How to Start

Standard starting doses for systemic estradiol are 0.05 mg per day via patch (changed twice weekly) or 0.75 mg per day via gel. For oral regimens, 1 mg estradiol daily is a common starting point, though transdermal is preferred for women with metabolic or clotting risk factors. [10]

Progestogen is added in one of two patterns. Sequential (cyclical) HRT delivers progestogen for 10-14 days each month and suits perimenopausal women who still have or recently had periods. Continuous combined HRT delivers progestogen daily alongside estrogen and suits women who are at least 12 months past their final period. Continuous regimens eventually eliminate withdrawal bleeds but often cause irregular spotting in the first 3-6 months. [1]

Symptom response typically appears within 4 weeks for hot flashes and within 8-12 weeks for mood, sleep, and joint symptoms. Dose adjustments should wait until at least 8 weeks at a given dose to allow steady-state levels to establish. If symptoms persist at a standard dose after 12 weeks, increasing estradiol to 0.1 mg patch or 1.5 mg gel is reasonable before switching route or adding adjunct therapy. [10]

Women who stop HRT abruptly rather than tapering often experience a rapid return of vasomotor symptoms, sometimes more intense than before starting. A gradual taper over 3-6 months, reducing the estradiol dose in steps of 50% every 6-8 weeks, generally produces a smoother discontinuation. No randomized data definitively prove one tapering schedule superior, but this approach aligns with current clinical consensus. [3]

Cognitive Health and HRT

Estrogen receptors are found throughout the brain, particularly in the hippocampus and prefrontal cortex. Rodent studies established neuroprotective effects of estradiol on neurons. Translating that to human clinical benefit has proved complicated.

The SWAN study (Study of Women's Health Across the Nation) followed 2,362 women through menopause and found that verbal memory declined measurably during the menopause transition, independent of age, and that the decline correlated with estradiol variability rather than absolute levels. [26] This supports the hypothesis that hormone fluctuation itself, not just low estrogen, affects cognition.

Current Menopause Society guidance (2023) does not support prescribing HRT for dementia prevention in the general population, given insufficient randomized trial evidence. [1] For women with POI, earlier initiation of HRT may reduce long-term dementia risk given the longer duration of estrogen deficiency otherwise incurred. [27] For surgical menopause before age 45, the risk of cognitive decline and all-cause dementia is significantly higher without HRT, per a Mayo Clinic cohort study of 1,837 women published in Neurology. [27]

The E3N cohort found that women who used estrogen-only therapy for 3 years or longer had a relative risk of Alzheimer's disease of 0.69 (95% CI 0.53-0.90) compared to never-users. [28] That is an observational finding subject to healthy-user bias, and it should not be used in isolation to justify initiating HRT primarily for brain protection. However, for women who are already appropriate HRT candidates based on symptoms, the cognitive data are reassuring rather than alarming.

Monitoring, Follow-Up, and Duration of Use

Baseline assessments before starting HRT should include blood pressure, weight, a breast examination, and a review of personal and family cancer history. Mammography should be current (every 1-2 years for women over 40 per the American Cancer Society). [29] A pelvic examination is not strictly required before starting HRT for typical candidates but helps identify other contributors to genitourinary symptoms.

Follow-up at 3 months after initiation allows dose adjustment and review of any irregular bleeding. Women on sequential HRT who experience breakthrough bleeding outside the expected progestogen window should have an endometrial assessment, typically transvaginal ultrasound. An endometrial thickness over 4 mm on ultrasound warrants biopsy to exclude hyperplasia. [10]

There is no absolute maximum duration for HRT in appropriate candidates. The Menopause Society states: "For women aged younger than 60 years or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favorable for treatment of bothersome menopause symptoms." [1] Annual reassessment of the benefit-risk balance is the standard approach, not a fixed stop date. Some women, particularly those with POI or severe symptoms, take HRT into their 60s or beyond with close monitoring.

Women over 60 initiating HRT for the first time face a less favorable risk profile, particularly for VTE and stroke with oral estrogen. Transdermal delivery remains lower risk in this age group, and any initiation after 60 should involve careful individual risk stratification. [9]

Non-Hormonal Alternatives for Women Who Cannot Take HRT

Some women have genuine contraindications to systemic estrogen. Effective non-hormonal options exist, though none match HRT's efficacy for moderate-to-severe vasomotor symptoms.

The FDA approved fezolinetant (Veozah), a neurokinin-3 receptor antagonist, in 2023 for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg daily reduced hot flash frequency by 59% versus 40% for placebo at week 12. [30] It carries a hepatotoxicity warning and requires liver function monitoring.

Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved antidepressant for hot flashes, shown to reduce frequency by approximately 33-65% in randomized trials. [31] Venlafaxine, gabapentin, and clonidine also have trial data supporting modest efficacy and are used off-label.

CBT-based interventions for menopause, tested in the MENOS trials (N=413), reduced hot flash problem rating by 50% at 6 months compared to usual care. [32] These work by altering the perceived distress of vasomotor symptoms rather than eliminating them, but for women with mild-to-moderate symptoms or those who prefer non-pharmacological approaches, the effect size is clinically meaningful.